Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-labetuzumab +/- Doxorubicin in Medullary Thyroid Cancer
NCT00004048Phase 2Completed
- Sponsor
- Garden State Cancer Center
- Start
- Sep 1998
- Primary completion
- May 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 labetuzumab in Medullary Thyroid Cancer (MTC), sponsored by Garden State Cancer Center. Started Sep 1998; status: completed.
02
Drugs
yttrium-90 labetuzumab
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT00004048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004048.